Literature DB >> 15968687

Clinical management of osteoporosis in women with a history of breast carcinoma.

Catherine Van Poznak1, Nicholas P Sauter.   

Abstract

Osteoporosis is a skeletal disorder that is characterized by low bone mass and compromised bone strength. Fractures are the clinically important consequence of osteoporosis and result not only in disability but also in excess mortality. Women who have a history of breast carcinoma may represent a unique population for whom screening and treatment for osteoporosis should be modified. A review of the English literature was performed that included original, review, consensus, and statement articles that were identified through Medline or National Institutes of Health-related links. According to the literature, osteoporosis constitutes a major public health problem. Approximately 55% of the U.S. population > or = 50 years of age has low bone mass (osteopenia or osteoporosis). Annually, > 200,000 women in the U.S. are diagnosed with breast carcinoma. Due to the high prevalence rates of both low bone mass and breast carcinoma in women, these two diseases commonly coexist in the same individuals. Women with a history of breast carcinoma may be at increased risk of developing bone loss and fragility fractures as a consequence of antineoplastic therapies. The majority of women treated for early-stage breast carcinoma do not develop recurrences, as a result of recent advances in therapy. Ensuring the diagnosis, prevention, and treatment of long-term toxicities and comorbid conditions like osteoporosis in breast carcinoma survivors is a serious concern and is of increasing importance. In this article, the authors address the evaluation and treatment of osteoporosis in women who have a history of early-stage breast carcinoma. (c) 2005 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15968687     DOI: 10.1002/cncr.21201

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  14 in total

Review 1.  Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls.

Authors:  Serge Cremers; Patrick Garnero
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Is there an association between high heparanase level and osteoporosis risk in breast cancer patients without clinical evidence of bone metastases?

Authors:  Kadri Altundag; Ozden Altundag; Mauricio Z Baptista; Selahattin Turen; Mustafa A Atik
Journal:  Osteoporos Int       Date:  2005-12       Impact factor: 4.507

3.  Periodontal health, perceived oral health, and dental care utilization of breast cancer survivors.

Authors:  L Susan Taichman; Jennifer J Griggs; Marita R Inglehart
Journal:  J Public Health Dent       Date:  2015-02-03       Impact factor: 1.821

4.  Bone targeted therapies in early breast cancer.

Authors:  Keo Tabane; Daniel A Vorobiof
Journal:  Curr Treat Options Oncol       Date:  2011-12

Review 5.  Potential implications of adjuvant endocrine therapy for the oral health of postmenopausal women with breast cancer.

Authors:  L Susan Taichman; Aaron M Havens; Catherine H Van Poznak
Journal:  Breast Cancer Res Treat       Date:  2012-09-18       Impact factor: 4.872

Review 6.  The management of osteoporosis in breast cancer survivors.

Authors:  Pamela Taxel; Palak Choksi; Catherine Van Poznak
Journal:  Maturitas       Date:  2012-09-25       Impact factor: 4.342

Review 7.  Bisphosphonate therapy for women with breast cancer and at high risk for osteoporosis.

Authors:  Gloria J Morris; Edith P Mitchell
Journal:  J Natl Med Assoc       Date:  2007-01       Impact factor: 1.798

Review 8.  Adjuvant Endocrine Therapy and Bone Health in Breast Cancer.

Authors:  Gregory A Clines; Palak Choksi; Catherine Van Poznak
Journal:  Curr Osteoporos Rep       Date:  2015-10       Impact factor: 5.096

9.  Bone integrity and bone metastases in breast cancer.

Authors:  Catherine Van Poznak; Cristina Nadal
Journal:  Curr Oncol Rep       Date:  2006-01       Impact factor: 5.075

Review 10.  Skeletal manifestations of treatment of breast cancer.

Authors:  Palak Choksi; Margaret Williams; Patricia M Clark; Catherine Van Poznak
Journal:  Curr Osteoporos Rep       Date:  2013-12       Impact factor: 5.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.